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Abstract
Methylenedioxymethamphetamine (MDMA) increases oxytocin, empathy, and prosociality.
Oxytocin plays a critical role in emotion processing and social behavior and has been shown
to mediate the prosocial effects of MDMA in animals. Genetic variants, such as single-nucle-
otide polymorphisms (SNPs), of the oxytocin receptor (OXTR) may influence the emotional
and social effects of MDMA in humans. The effects of common genetic variants of the
OXTR (rs53576, rs1042778, and rs2254298 SNPs) on the emotional, empathogenic, and
prosocial effects of MDMA were characterized in up to 132 healthy subjects in a pooled anal-
ysis of eight double-blind, placebo-controlled studies. In a subset of 53 subjects, MDMA pro-
duced significantly greater feelings of trust in rs1042778 TT genotypes compared with G
allele carriers. The rs53576 and rs225498 SNPs did not moderate the subjective effects of
MDMA in up to 132 subjects. None of the SNPs moderated MDMA-induced impairments in
negative facial emotion recognition or enhancements in emotional empathy in the Multiface-
ted Empathy Test in 69 subjects. MDMA significantly increased plasma oxytocin concentra-
tions. MDMA and oxytocin concentrations did not differ between OXTR gene variants. The
present results provide preliminary evidence that OXTR gene variations may modulate
aspects of the prosocial subjective effects of MDMA in humans. However, interpretation
should be cautious due to the small sample size. Additionally, OXTR SNPs did not moderate
the subjective overall effect of MDMA (any drug effect) or feelings of “closeness to others”.
Trial registration: ClinicalTrials.gov: http://www.clinicaltrials.gov, No: NCT00886886,
NCT00990067, NCT01136278, NCT01270672, NCT01386177, NCT01465685,
NCT01771874, and NCT01951508.
Introduction
3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is recreationally used for its effects
on empathic feelings and sociability [1, 2]. MDMA has also been shown to reduce the percep-
tion of negative emotions and enhance empathy [1, 3–6], effects that could potentially be use-
ful in MDMA-assisted psychotherapy [7]. MDMA mainly causes the release of serotonin,
norepinephrine, and dopamine [8, 9] but also increases oxytocin [1, 10–14]. Many similarities
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are seen in the effects of MDMA and oxytocin on emotion processing and social behavior. For
example, MDMA improves the identification of positive facial emotions and impairs the rec-
ognition of negative facial emotions [1, 4, 12, 15]. Similar effects were observed after intranasal
administration of oxytocin [16, 17]. Intranasal administration of oxytocin increased trust and
productive communication [18, 19]. MDMA similarly increased feelings of trust, openness,
and closeness to others [1, 3]. Oxytocin increased generosity, and MDMA increased prosocial
economic behavior [1]. One study showed significant within-subject correlations between
MDMA-induced changes in prosocial feelings and changes in plasma oxytocin concentrations
[10] implicating oxytocin as a mediator of the prosocial effects of MDMA. However, many
other studies failed to find associations between oxytocin concentrations and the subjective,
emotional, empathic, or prosocial effects of MDMA across subjects [1, 4, 12, 20, 21]. Animal
studies showed that MDMA-induced prosocial effects in rats and mice could be blocked by
oxytocin receptor (OXTR) antagonists [13, 22] also supporting a role for oxytocin in the pro-
social effects of MDMA in animals. However, whether oxytocin is indeed a mediator of the
effects of MDMA in humans is unclear. Oxytocin receptor blockade in the human brain may
be challenging because OXTR blockers, such as atosiban, do not cross the blood-brain barrier.
Correlational analyses are also problematic because plasma oxytocin concentrations may not
necessarily reflect oxytocin levels in the brain [23].
While MDMA induces positive mood effects and prosociality in most subjects, negative
mood effects have also been reported [24–27]. Genetic variations could explain some of the
interindividual differences in the response to MDMA. Specifically, several genetic variations of
the OXTR that are caused by single-nucleotide polymorphisms (SNPs) are associated with
human social behavior or traits [28, 29]. One approach to indirectly testing the role of oxytocin
in the effects of MDMA is to evaluate the moderating role of different SNPs of the OXTR gene
in the prosocial and empathogenic effects of MDMA. In one study on the role of OXTR gene
variants in the effects of MDMA, MDMA increased sociability in carriers of the G allele of the
OXTR rs53576 SNP but not in individuals with the AA genotype [30]. Furthermore in studies
without MDMA, the common GG variant of rs53576 has been associated with greater empathy
and trust, seeking emotional support in times of distress, and less stress reactivity [31]. In con-
trast, carriers of the A allele presented lower sociability and lower sensitivity to oxytocin-
induced enhancements in emotion recognition [32]. In addition to the rs53576 SNP, two of
the most studied SNPs of the OXTR gene are rs1042778 and rs2254298. These SNPs were more
likely to show an association to prosociality or other effects of oxytocin than other SNPs stud-
ied. For example, among 15 SNPs, the rs1042778 showed the most significant associations with
prosociality [33]. Carriers of the G allele of the rs1042778 SNP presented greater prosocial
behavior in an economic exchange game also used in the present study [33] and more sensitive
parenting [34]. The rs2254298 SNP has been associated with autism, attachment behavior, and
depression [35–37] and rs2254298 and rs53576were the most informative among 27 OXTR
SNPs in a small sample of 38 subjects to predict responses to oxytocin in autism [38].
In the present study, we exploratorily investigated whether the OXTR rs53576, rs1042778,
and rs2254298 SNPs influence the social subjective, emotional, empathic, and prosocial effects
of MDMA. Additionally, we sought to replicate previous findings regarding the role of the
OXTR rs53576 SNP in the prosocial response to MDMA [30].
Materials and methods
Study design
This was a pooled analysis of eight Phase I double-blind, placebo-controlled, crossover studies
in healthy subjects that used similar methods [8, 39–45]. These studies included a total of 136
OXTR and MDMA
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healthy subjects and were conducted between April 2009 and December 2014. Seven studies
each included 16 subjects (112 total subjects) who received 125 mg MDMA twice, once alone
and once after pretreatment with a medication [8, 39–43, 45]. However, in the present analysis,
only data from the MDMA-alone and placebo sessions were used. An additional study
included 24 subjects who received 125 mg MDMA once without pretreatment [44]. In all of
the studies, the washout periods between the single dose administrations were at least 7 days to
exclude carry-over effects. The studies were all registered at ClinicalTrials.gov (NCT00886886,
NCT00990067, NCT01136278, NCT01270672, NCT01386177, NCT01465685, NCT01771874,
and NCT01951508). All of the studies were approved by the local ethics committee and Swiss
Agency for Therapeutic Products (Swissmedic). The studies were conducted in accordance
with the Declaration of Helsinki. Informed consent was obtained from all of the participants
who were included in the studies. All of the subjects were paid for their participation. Pharma-
cokinetic and safety data from the same studies have been reported elsewhere [26, 46, 47].
Subjects
A total of 136 healthy subjects of European descent, aged 18–44 years (mean ± SD = 24.8 ± 4
years), were recruited from the University of Basel campus and participated in the study. One
genotyping sample was missing, and three participants did not give consent for genotyping,
resulting in the analysis of data from 132 subjects (64 men, 68 women). The mean ± SD body
weight was 68 ± 10 kg (range: 46–90 kg).
The detailed exclusion criteria were reported elsewhere [8, 39, 40, 42] and included a his-
tory of psychiatric disorders, physical illness, a lifetime history of using illicit drugs more than
five times (with the exception of past cannabis use), illicit drug use within the last 2 months,
and illicit drug use during the study, determined by urine tests before the test sessions.
Study drug
(±)MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was administered orally in a
single dose of 125 mg that was prepared as gelatin capsules (25 and 100 mg, Bichsel Laborato-
ries, Interlaken, Switzerland). Similar amounts of MDMA are found in ecstasy pills and have
been used in clinical studies in patients [7]. The doses were not adjusted for body weight or
sex. The dose per body weight (mean ± SD) was 1.9 ± 0.3 mg/kg (1.7 ± 0.2 mg/kg for men and
2.1 ± 0.3 mg/kg for women; range: 1.4–2.7 mg/kg).
Genotyping
Genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen,
Hombrechtikon, Switzerland) and automated QIAcube system. Genotyping was performed
using commercial TaqMan SNP genotyping assays (LuBio Science, Lucerne, Switzerland). The
OXTR is located on the short arm of chromosome 3 (3p25) and has three introns and four exons.
We genotyped three OXTR SNPs: rs53576 (c.922+4581T>C, position [GRCh37]: chr3:8804371,
assay: C___3290335_10), rs1042778 (c.118C>A, position [GRCh37]: chr3:8794545, assay:
C___7622140_30), and rs2254298 (c.922+6724C>T, position [GRCh37]: chr3:8802228, assay:
C__15981334_10). Linkage disequilibrium analysis between the SNPs were performed using Hap-
loview (Broad Institute).
Subjective effects
Visual Analog Scales (VASs) were repeatedly applied to assess subjective effects over time [1].
The VAS “any drug effect” was presented as 100 mm horizontal lines (0–100%), marked from
OXTR and MDMA
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“not at all” on the left to “extremely” on the right. The VASs “closeness to others,” “trust,”
“want to be hugged,” “want to hug,” “want to be alone,” and “want to be with others” were
bidirectional (±50%). “Trust,” “want to be hugged,” “want to hug,” “want to be alone,”
and”want to be with others” were assessed in 53 subjects. The VASs were administered before
and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo administration.
Emotion recognition
To measure emotion recognition, we used the Facial Emotion Recognition Task (FERT),
which is sensitive to the effects of MDMA [3, 5, 12, 43] and other serotonergic substances [48].
The task included 10 neutral faces and 160 faces that expressed one of four basic emotions (i.e.,
happiness, sadness, anger, and fear), with pictures morphed between 0% (neutral) and 100% in
10% steps. Two female and two male pictures were used for each of the four emotions. The sti-
muli were presented in random order for 500 ms and then were replaced by the rating screen
where the participants had to indicate the correct emotion. The outcome measure was accu-
racy (proportion correct) and misclassification (emotions that were indicated incorrectly). The
FERT was performed 90 min after drug administration. FERT data were available from 69 sub-
jects. The genotype distribution for this subsample was: rs1042778 (28 GG, 33 GT, 8 TT),
rs53576 (30 GG, 25 AG, 14 AA), and rs2254298 (57 GG, 12 AG/AA).
Empathy
The Multifaceted Empathy Test (MET) is a reliable and valid task that assesses the cognitive
and emotional aspects of empathy [49]. The MET is sensitive to oxytocin [17], MDMA [1, 3,
20], and other psychoactive substances [48]. The computer-assisted test consisted of 40 photo-
graphs that showed people in emotionally charged situations. To assess cognitive empathy, the
participants were required to infer the mental state of the subject in each scene and indicate
the correct mental state from a list of four responses. Cognitive empathy was defined as the
percentage of correct responses relative to total responses. To measure emotional empathy, the
subjects were asked to rate how much they were feeling for an individual in each scene (i.e.,
explicit emotional empathy) and how much they were aroused by each scene (i.e., implicit
emotional empathy) on a 1–9 point scale. The latter rating provides an inherent additional
assessment of emotional empathy, which is considered to reduce the likelihood of socially
desirable answers. The three aspects of empathy were each tested with 20 stimuli with positive
valence and 20 stimuli with negative valence, resulting in a total of 120 trials. The MET was
performed 90–180 min after drug administration. MET data were available from 69 subjects.
The genotype distribution for this subsample was: rs1042778 (28 GG, 33 GT, 8 TT), rs53576
(30 GG, 25 AG, 14 AA), and rs2254298 (57 GG, 12 AG/AA).
Prosociality
We used the paper version of the validated Social Value Orientation (SVO) test to assess social
behavior [50]. The SVO test is sensitive to MDMA [1] and other psychoactive substances [48].
In this economic resource allocation task, prosociality is defined as behavior that maximizes
the sum of resources for the self and others and minimizes the difference between the two. The
test consists of six primary and nine secondary SVO slider items with a resource allocation
choice over a defined continuum of joint payoffs [50]. The participants were instructed to
choose a resource allocation that defined their most preferred joint distribution between them-
selves and another person. The allocated funds had real value, and four randomly selected
subjects received the funds they earned. Mean allocations for the self and the other were calcu-
lated [1, 50], and the inverse tangent of the ratio of these two means produced an angle that
OXTR and MDMA
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indicated the participants’ SVO index. A smaller SVO angle indicates more individualistic or
competitive behavior, and a larger SVO angle indicates more prosocial or even altruistic
behavior. The nine secondary items were used to differentiate between two different prosocial
motivations (inequality aversion and joint gain maximization). The inequality-aversion index
was calculated as previously described [50]. An index of 0 indicates perfect inequality aversion,
and 1 indicates maximal preference for joint gain maximization. The SVO test was performed
3–4 h after drug administration. SVO primary data and the inequality-aversion index were
available from 69 and 33 subjects, respectively. The genotype distribution for this subsample
was: rs1042778 (28 GG, 33 GT, 8 TT), rs53576 (30 GG, 25 AG, 14 AA), and rs2254298 (57 GG,
12 AG/AA) and rs1042778 (15 GG, 15 GT, 3 TT), rs53576 (12 GG, 15 AG, 6 AA), and
rs2254298 (26 GG, 7 AG/AA), respectively.
Plasma concentrations of oxytocin and MDMA
The plasma concentration of oxytocin has been shown to peak 2 h after MDMA administra-
tion [10] and was therefore measured at baseline and 2 h after drug administration and ana-
lyzed as described previously [4, 23, 51]. The plasma level of MDMA was determined 1 h
before and 0.5, 1, 1.5, 2, 3, 4, and 6 h after drug administration and analyzed as described previ-
ously [8].
Statistical analysis
Subjective drug effects on the VASs were determined as the area under the effect-time curve
from 0 to 6 h (AUEC6) after drug administration using the trapezoidal method in Phoenix
WinNonlin (version 6.4, Pharsight, Certara L.P., St. Louis, MO, USA). The statistical analyses
were performed using Statistica 12 software (StatSoft, Tulsa, OK, USA). The effects of MDMA
on subjective effect ratings and plasma oxytocin concentrations were expressed as differences
from placebo. Repeated-measured analyses of variance (ANOVAs), with drug (MDMA vs. pla-
cebo) as the within-subjects factor, were used to evaluate drug effects. One-way ANOVAs,
with genotype group as the between-subjects factor, followed by the Tukey post hoc test were
used to evaluate the effects of genotype on the effects of MDMA (differences from placebo).
Additional ANOVAs including plasma concentrations of MDMA and/or oxytocin as covari-
ates were conducted as well as sex differences were included by adding sex as an additional
between-subjects factor to the analyses to exclude confounding by any of these variables. This
showed that the results were not confounded by oxytocin plasma levels, or sex, or differences
in plasma concentrations of MDMA, that corrects for differences in body weight, dosing, or/
and known and unknown activity differences in metabolizing enzymes [46, 47]. The reported
results are from analysis with MDMA plasma concentration AUC6 and oxytocin plasma con-
centration change at 2 h as covariates with the exception of the VAS “any drug effect” and
“closeness to others” for which only MDMA plasma concentration AUC6 was corrected due to
the lack of oxytocin plasma concentration data for subjects from the first two studies [8, 41].
The level of significance was set to p< 0.05. The Nyholt correction method was used to
account for multiple comparisons and flagged separately [52]. We thereby corrected for the 7
VASs, 3 emotions in the FERT, emotional empathy in the MET, and 2 items in the SVO which
have all been shown sensitive to the effects of MDMA and for each of the 3 tested SNPs ([7+3
+1+2] × 3), resulting in 39 variables and an effective number of independent variables (Veff) of
28.96 according to Nyholt and a corrected significance threshold to keep Type I error rate at
5% of p< 0.0017. For the analysis of the rs2254298 SNP, the AA and AG genotypes were
pooled as A allele carriers because only one subject had the AA genotype.
OXTR and MDMA
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Results
Genotyping
The distribution of the alleles and genotypes did not differ from distributions reported else-
where in Caucasian cohorts (Ensembl database release 86, Oct 2016). The rare allele frequen-
cies for rs53576, rs1042778, and rs2254298were A (93 [35%]), T (101 [38%]), and A (20
[11%]), respectively. No linkage disequilibrium was detected between the tested SNPs (S1 Fig).
Subjective effects
On the VASs, MDMA increased the AUEC6 values for “any drug effect” (F1,131 = 544, p< 0.001),
“closeness” (F1,131 = 57, p< 0.001), “trust” (F1,52 = 33; p< 0.001), “want to be hugged” (F1,52 =
6.6, p< 0.05), “want to hug” (F1,52 = 7.6, p< 0.01), and “want to be with others” (F1,52 = 20,
p< 0.001) and decreased feelings of “want to be alone” (F1,52 = 21, p< 0.001, Fig 1, Table 1).
The effects of the OXTR rs1042778 SNP on the subjective effects of MDMA are shown in
Table 1, Fig 1, and S1 Table. MDMA produced increases in “trust” (F1,49 = 14, p< 0.001),
“want to be hugged” (F1,49 = 5.3, p< 0.05), and “want to be with others” (F1,49 = 6.5, p< 0.05)
in the TT genotype group compared with the G allele carriers. MDMA lowered ratings of
“wanting to be alone” more in subjects with the TT genotype compared with G allele carriers
(F1,49 = 4.5, p< 0.05). Using Nyholt correction for the multiple comparisons, only MDMA
effects on “trust” was significantly altered by the rs1042778 SNP. The OXTR rs53576 and
rs2254298 SNPs did not alter the subjective effects of MDMA (Table 1).
Emotion recognition
On the FERT, MDMA impaired the recognition of fearful (F1,68 = 47, p< 0.001), sad (F1,68 =
14, p< 0.001), and angry (F1,68 = 16, p< 0.001) faces compared with placebo. None of the
OXTR gene variants moderated the effects of MDMA on the FERT.
Empathy
MDMA increased explicit emotional empathy for positive emotions (F1,68 = 7.6, p< 0.01) com-
pared with placebo. None of the OXTR gene variants altered the effects of MDMA on the MET.
Prosociality
MDMA produced a near-significant trend toward an increase in the SVO angle compared
with placebo (F1,68 = 3.1, p = 0.08). MDMA reduced the inequality-aversion index (F1,32 = 9.3,
p< 0.01) in subjects with a prosocial orientation, indicating a shift from joint gain maximiza-
tion to inequality aversion. The rs53576 and rs1042778 SNPs moderated the MDMA-induced
increase in inequality aversion (S2 Fig). MDMA significantly reduced the inequality-aversion
index in the rs53576AA genotype group compared with G allele carriers (F1,31 = 9.4, p< 0.01).
MDMA also reduced inequality-aversion in the rs1042778GG genotype group compared with
T allele carriers (F1,29 = 5.6, p< 0.05). T allele carriers who received placebo also had a lower
inequality-aversion index (corresponding to greater inequality-aversion) compared with sub-
jects with the GG genotype (p< 0.05). However, if corrected for multiple comparisons none
of the OXTR genetics influence SVO findings significantly.
Plasma concentrations of oxytocin and MDMA
Plasma oxytocin and MDMA concentrations are shown in Table 1. Oxytocin concentrations
were significantly elevated 2 h after MDMA administration compared with placebo (placebo:
OXTR and MDMA
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Fig 1. Effect of the OXTR rs1042778 SNP on the subjective effects of MDMA. MDMA produced greater “trust,” “want to be hugged,” “want
to hug,” and “want to be with others” and reduced “want to be alone” in the TT group (n = 5) compared with the GG/GT group (n = 48, Table 1
and S1 Table). The data are expressed as mean ± SEM. MDMA or placebo was administered at time = 0.
https://doi.org/10.1371/journal.pone.0199384.g001
OXTR and MDMA
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19 ± 39 pg/ml; MDMA: 74 ± 70 pg/ml; F1,99 = 62, p< 0.001). Plasma oxytocin and MDMA
concentrations similarly increased across all OXTR gene variants (Table 1). MDMA peak con-
centrations and AUC6 values were (mean ± SD) 224 ± 48 ng/mL and 950 ± 207 ng×h/mL in
the total of 132 subjects. There was acute tolerance to the subjective response to MDMA.
Discussion
The main finding of this study was that the OXTR rs1042778 SNP influenced the typical
empathogenic and prosocial feelings that are produced by MDMA, including enhancements
of “trust”. Similar modulation of the prosocial effects of MDMA was previously reported for
the OXTR rs53576 SNP [30] but not rs1042778 SNP. These findings suggest that humans may
respond differently to the typical subjective effects of MDMA, depending on their OXTR
genetics. The results indirectly indicate a possible role for oxytocin in the subjective effects of
MDMA, similar to its interoceptive effects in rats [53]. Animal studies have shown that oxyto-
cin mediates the prosocial effects of MDMA [13, 14, 54]. We observed lower subjective proso-
ciality after MDMA administration in carriers of the G allele of the rs1042778 SNP. Greater
prosociality [33] and lower antisocial behavior [55] have been associated with the G allele in
the absence of treatment. Our placebo condition was unsuitable for assessing differences in
prosociality between subjects in the absence of treatment. Altogether, however, the findings
are consistent with the notion that subjects with lower sociality may respond more to the pro-
social effects of MDMA or oxytocin [56].
Table 1. Effects of oxytocin receptor rs53576, rs1042778, and rs2254298 polymorphism groups on the response to MDMA (mean±SD and statistics).
SNP rs1042778 SNP rs53576 SNP rs2254298
GG/
GT
TT F p value p
valuea
GA/
GG
AA F p
value
p
valuea
GG AA/
AG
F p
value
p
valuea
N (%) 113
(86)
19 (14) 113
(86)
19 (14) 105
(80)
27 (20)
Male, N (%) 57 (50) 7 (37) 52 (46) 12 (63) 51 (49) 13 (48)
MDMA plasma concentration
AUC6 (ng
h/mL)
954
±212
924
±179
0.34 NS NS 956
±205
914
±219
0.68 NS NS 941
±208
985
±200
0.99 NS NS
MDMA peak concentrations (ng/
mL)
225
±49
223±41 0.02 NS NS 226
±47
214
±53
1 NS NS 222
±47
235
±50
1.8 NS NS
Oxytocin Δplasma concentration
at 2h (pg/mL)b
53±63 64±101 0.33 NS NS 55±71 53±60 0.01 NS NS 53±68 63±74 0.35 NS NS
Visual Analog Scale rating ΔAUEC6
Any drug effect 195
±95
196
±107
0.16 NS NS 193
±98
205
±88
1.14 NS NS 188
±95
221
±97
1.55 NS NS
Closeness to others 37±57 64±87 3.89 0.051 NS 39±60 54±74 1.59 NS NS 41±65 41±51 0.07 NS NS
Trustc 46±64 153±65 14.03 <0.001 0.014 58±75 52±59 0.02 NS NS 50±72 86±60 1.06 NS NS
Want to be huggedc 20±68 105
±129
5.27 0.026 NS 29±80 23±78 0.03 NS NS 26±82 37±59 0.02 NS NS
Want to hugc 22±65 63±101 1.53 NS NS 29±70 18±66 0.01 NS NS 26±72 26±57 0.15 NS NS
Want to be alonec -55
±97
-153
±108
4.49 0.039 NS -55
±96
-91
±116
2.62 NS NS -58
±105
-93
±78
0.28 NS NS
Want to be with othersc 43±77 140
±120
7.28 0.010 NS 47±85 67±88 1.56 NS NS 48±91 70±45 0.09 NS NS
N, number of subjects; AUEC, area under the effect-time curve; SD, standard deviation; NS, not significant; Δ, values are change scores from placebo.
ap value additionally corrected for multiple comparisons according to the Nyholt correction.
bN = 101 (rs1042778: 87 GG/GT, 14 TT; rs53576: 83 GG/AG, 18 AA; rs2254298: 81 GG, 20 AG/AA).
cN = 53 (rs1042778: 48 GG/GT, 5 TT; rs53576: 40 GG/AG, 13 AA; rs2254298: 44 GG, 9 AG/AA).
https://doi.org/10.1371/journal.pone.0199384.t001
OXTR and MDMA
PLOS ONE | https://doi.org/10.1371/journal.pone.0199384 June 18, 2018 8 / 14
In the present study, we failed to replicate a previous finding of moderation of the subjective
prosocial effects of MDMA by the rs53576 SNP [30]. This previous study showed that carriers
of the AA genotype at the rs53576 locus were not susceptible to the prosocial effect of 1.5 mg/
kg MDMA [30]. However, this previous study assessed “sociability” as a combined outcome of
several VASs, including “friendly,” “sociable,” “confident,” “playful,” and “loving” using prin-
cipal component analysis [30]. Additionally, the effect of rs53576was observed only at a dose
of 1.5 mg/kg MDMA, whereas opposite effects were observed with 0.75 mg/kg MDMA [30].
The discrepant findings between these two studies may be partially explained by the different
scales that were used. The findings may also indicate that the MDMA effect modulation by dif-
ferent OXTR SNPs is not very robust across studies and rather small.
The effects of MDMA on the FERT and MET in the present study were consistent with
studies by other researchers who used the same tests [5, 20]. The present study found that the
rs53576, rs1042778, and rs2254298 SNPs did not influence MDMA-induced impairments in
the recognition of fearful, sad, and angry faces or increases in emotional empathy. No other
data are available on the effects of other OXTR gene variants on MDMA-induced changes in
tests of emotion processing or empathy. In contrast to the present study, the effect of intranasal
oxytocin on dynamic face recognition has previously been shown to be modulated by OXTR
SNP haplotypes, including the SNPs that were studied herein [32].
On the SVO test, MDMA produced a trend toward an increase in prosocial behavior and
increased inequality aversion. We previously reported a significant increase in prosociality and
a trend toward an increase in inequality aversion from a subset of the present data [1]. A novel
finding of the present study was that MDMA increased inequality-aversion and thus a prefer-
ence for fairness only in subjects with the rs53576AA or rs1042778GG genotypes, indicating a
role for these OXTR gene variants in MDMA’s effect on social behavior. However, the
MDMA-induced increase in preference for fairness in rs1042778GG subjects appears to con-
flict with the smaller increase in trust in these subjects (S1 Table). Additionally, rs1042778GG
individuals presented lower inequality aversion compared with T allele carriers who received
placebo. Higher prosociality on the SVO test has previously been reported in G allele carriers
[33], but differences in the inequality-aversion index were not studied because this scale was
only added later to the SVO test [50]. Furthermore, the OXTR rs1042778, rs53576, and
rs2254298 SNPs had no effects in two other economic games (i.e., dictator game and trust
game; [57]). The findings in the SVO tests are conclusive but need to be interpreted with cau-
tion, since they did not survive the correction for multiple comparisons and the total number
of subjects in this subset was reduced to 33 due to the limiting calculation of the inequality
aversion [50].
The present study has several limitations. First, the study was mostly exploratory and the
findings would need to be confirmed in larger studies. Second, not all outcome measures were
used in all of the subjects, thus limiting the sample size and also increasing the risk of Type I
errors. Third, we tested only three OXTR SNPs. Other SNPs or haplotypes may also play a role
[32]. Fourth, MDMA causes the release of oxytocin, monoamines [8, 9], and arginine vaso-
pressin [51]. The latter two are well known to influence social cognition and behavior [58].
MDMA also increases cortisol and other corticosteroids [59, 60] and oxytocin and cortisol
may interact to influence the response to MDMA and these interactions need further study
[21]. Finally, cultural and early environmental background plays an uncertain role in the
results of genetic studies, especially studies of OXTRs. For example, studies of the rs2254298
SNP reported different results in Caucasian and Asian subjects [35, 61].
The present findings of individual differences in the response to MDMA that depended on
OXTR genetics need to be confirmed and might have implications for MDMA-assisted psy-
chotherapy [7] and may contribute to more personalized treatment. Therapeutic studies that
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use MDMA in patients should genotype OXTR SNPs and test for polymorphisms of the genes
that regulate the metabolism of MDMA [46, 47].
Conclusion
The OXTR rs1042778 SNP but not the rs53576 or rs2254298 SNPs altered the typical MDMA-
induced feelings of trust. A previous finding of a moderating influence of the rs53576 on the
socio-emotional effect of MDMA could not be replicated indicating a chance finding. Addi-
tionally, after correction for multiple comparisons OXTR SNPs did not moderate the subjec-
tive overall effect of MDMA (any drug effect) or feelings of “closeness to others” in the total
larger study sample of 132 subjects. Thus, the results are preliminary and should be interpreted
with caution due to multiple comparisons and small genotype group sample sizes.
Supporting information
S1 Fig. Linkage disequilibrium across the determined SNPs. Estimates of the square of the
correlation coefficient (r2) were calculated for each pairwise comparison of SNPs based on
data from our study cohort.
(TIF)
S2 Fig. OXTR rs53576 and rs104278 SNPs moderate the effects of MDMA on the SVO
Inequality-aversion index. (a) MDMA reduced the inequality-aversion index in the OXTR
rs53576 AA genotype group (n = 6) but not in the GG/GA genotype group (n = 27, p<
0.01). (b) MDMA reduced the inequality-aversion index in the OXTR rs1042778 GG genotype
group (n = 15) but not in the TT/TG genotype group (n = 18, p< 0.05, p< 0.01). The data
are expressed as mean ± SEM. If corrected for multiple comparisons none of the OXTR genet-
ics significantly influence SVO findings. An inequality-aversion index of 0 indicates perfect
inequality aversion (maximal fairness), and 1 indicates maximal preference for joint gain max-
imization in subjects with a prosocial value orientation.
(TIF)
S1 Table. Effects of oxytocin receptor rs53576 and rs1042778 polymorphisms (all allele
groups) on the response to MDMA (mean±SD and statistics). N, number of subjects;
AUEC, area under the effect-time curve; SD, standard deviation; NS, not significant; D, values
are change scores from placebo; p value < 0.01 compared to rs1042778 TT. ap value addi-
tionally corrected for multiple comparisons according to the Nyholt correction. bN = 101
(rs1042778: 39 GG, 48 GT, 14 TT; rs53576: 44 GG, 39 AG, 18 AA; rs2254298: 80 GG, 21
AG/AA). cN = 53 (rs1042778: 21 GG, 27 GT, 5 TT; rs53576: 23 GG, 17 AG, 13 AA; rs2254298:
44 GG, 9 AG/AA).
(XLSX)
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